RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib (RECORD-1)
This study has been completed.
First Posted: December 12, 2006
Last Update Posted: January 15, 2013
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )